Eribulin was administered intravenously at a dose of 1.4 mg/m2 on days 1 and 8 of each 21-day cycle. The physician could adjust the eribulin dose based on the severity of adverse events. The treatment was continued until the disease being progressed or encounter intolerable of toxicity.
Free full text: Click here